Order Code SNS Supplemental Newborn Screen, Blood Spot
Reporting Name
Supplemental Newborn Screen, BSUseful For
Presymptomatic identification of disorders to allow for early initiation of treatment and consequent improvement in the long-term prognosis of affected patients
The conditions identifiable by amino acid and acylcarnitine analysis are detected by supplemental newborn screening using tandem mass spectrometry (MS/MS) as described here.
Analyte (assay platform) |
ACMG recommended conditions |
Additional conditions/treatment detectable by MS/MS |
|
Core condition |
Secondary targets |
||
Amino acids (MS/MS) |
|||
Phe |
PKU |
BS HPA REG |
TPN |
Leu/Ile, Val |
MSUD |
|
TPN |
Met |
HCY |
Met |
TPN, nonspecific liver disease |
Cit, Arg, ASA |
ASA CIT |
ARG CIT-II |
|
Tyr |
TYR-I |
TYR-II TYR-III |
Nonspecific liver disease |
GUAC |
GAMT |
|
|
Acylcarnitines (MS/MS) |
|||
C0 |
CUD |
|
Maternal CUD, maternal GA-I, maternal MCAD |
C3 |
CblA, Cbl B MUT PA |
Cbl C, Cbl D |
|
C4 |
|
IBDH SCAD |
FIGLU |
C5 |
IVA |
SBCAD |
Antibiotics containing pivalic acid |
C5-OH |
BKT HMG MCC MCD |
MGA-I MHBD |
Maternal MCC, biotinidase deficiency |
C8 |
MCAD |
GA-II MCKAT M/SCHAD |
|
C3-DC |
|
MAL |
|
C10:2 |
|
DR |
|
C5-DC |
GA-I |
|
|
C14:1, C16, C18:1 |
VLCAD |
CACT CPT-I CPT-II |
|
C16-OH |
LCHAD TFP |
|
|
m/z 225<399<473 |
|
|
Dextrose infusion |
m/z 342 (C8:1) |
|
|
Artifact often observed in premature neonates |
m/z 470 (C16:1OH) |
|
|
Cefotaxime metabolite |
Succinylacetone |
TYR-I |
|
|
This test is not appropriate for metabolic screening of symptomatic patients.
Testing Algorithm
For more information see:
-Newborn Screen Follow-up for Elevated C5-DC
-Newborn Screen Follow-up for Isolated Elevation of C3-DC
-Newborn Screen Follow-up for Elevated C5-OH
-Newborn Screen Follow-up for Isolated Elevation of C3
-Newborn Screen Follow-up for Elevated C14:1 ± Other Long-Chain Acylcarnitine
-Newborn Screen Follow-up for Decreased Free Carnitine (C0)
-Newborn Screen Follow-up for Elevated C16 ± C18:1 Acylcarnitines
-Newborn Screen Follow-up for Elevated C0; Elevated C0/(C16+C18)
-Newborn Screen Follow-up for Elevated C16-OH ± C18-OH
-Newborn Screen Follow-up for Elevated C4-OH Acylcarnitine
-Newborn Screen Follow-up for Elevated C4 and C5 Acylcarnitine ±Other Elevated Acylcarnitines
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Whole bloodAdditional Testing Requirements
A repeat specimen is required within 1 week of birth for infants tested before they are 12 hours old.
Specimen Required
Patient must be older than 12 hours and less than 1 week of age.
Supplies: Card-Blood Spot Collection Filter Paper (T493)
Preferred: Blood Spot Collection Card
Acceptable: Whatman Protein Saver 903 Paper, Munktell, PerkinElmer 226 filter paper, or local newborn screening card
Specimen Volume: 3 Blood spots
Collection Instructions:
1. Do not use device or capillary tube containing EDTA to collect specimen.
2. Completely fill at least 3 circles on the filter paper card (approximately 100 microliters blood per circle).
3. Let blood dry on the Blood Spot Collection Card at ambient temperature in a horizontal position for 3 hours.
4. Do not expose specimen to heat or direct sunlight.
5. Do not stack wet specimens.
6. Keep specimen dry.
Additional Information:
1. For collection instructions, see Blood Spot Collection Instructions.
2. For collection instructions in Spanish, see Blood Spot Collection Card-Spanish Instructions (T777).
3. For collection instructions in Chinese, see Blood Spot Collection Card-Chinese Instructions (T800).
Specimen Minimum Volume
1 Blood spot
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole blood | Ambient (preferred) | FILTER PAPER | |
Frozen | FILTER PAPER | ||
Refrigerated | FILTER PAPER |
Special Instructions
- Request for Original Newborn Screening Card
- Blood Spot Collection Card-Spanish Instructions
- Blood Spot Collection Card-Chinese Instructions
- Blood Spot Collection Instructions
- Newborn Screen Follow-up for Isolated Elevation of C3-DC
- Newborn Screen Follow-up for Elevated C5-DC
- Newborn Screen Follow-up for Elevated C5-OH
- Newborn Screen Follow-up for Isolated Elevation of C3
- Newborn Screen Follow-up for Decreased Free Carnitine (C0)
- Newborn Screen Follow-up for Elevated C14:1 ± Other Long-Chain Acylcarnitine
- Newborn Screen Follow-up for Elevated C16 ± C18:1 Acylcarnitines
- Newborn Screen Follow-up for Elevated C8 Acylcarnitine with Lesser Elevations of C6 and C10 Acylcarnitines
- Newborn Screen Follow-up for Elevated C0; Elevated C0/(C16+C18)
- Newborn Screen Follow-up for Elevated C16-OH ± C18-OH
- Newborn Screen Follow-up for Elevated C4 and C5 Acylcarnitine ±Other Elevated Acylcarnitines
- Newborn Screen Follow-up for Elevated C4-OH Acylcarnitine
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Saturday
CPT Code Information
83789
Genetics Test Information
This screening test includes all disorders recommended by the American College of Medical Genetics detectable by tandem mass spectrometry.(1)
Method Description
In the United States, every newborn undergoes state-mandated screening on the second day of life or before leaving the hospital. Blood from a heel prick is dripped onto a filter paper card. The blood is left to dry before sending the filter paper card along with pertinent demographic information to the screening laboratory.
Blood for the supplemental newborn screening is collected in the same way and then sent to the Biochemical Genetics Laboratory, after obtaining parental consent. A 1/8-inch (3-mm) disk is punched out of the blood spot onto 96-well plate. Then, the amino acids and acylcarnitines are extracted by the addition of methanol and known concentrations of isotopically labeled amino acids and acylcarnitines as internal standards. The extract is moved to another 96-well plate, dried under a stream of nitrogen, and derivatized by the addition of n-butanol hydrochloric acid. In a parallel process, succinylacetone is extracted from the residual blood spot, derivatized with an acidic hydrazine solution, evaporated and combined with the amino acid and acylcarnitine extract amino acids and acylcarnitines are measured as their butyl esters with the hydrazone derivative of succinylacetone by electrospray tandem mass spectrometry. The concentrations of the analytes are established by computerized comparison of ion intensities of these analytes to that of the respective internal standards.(Turgeon C, Magera MJ, Allard P, et al. Combined newborns screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. Clin Chem. 2008;54[4]:657-664; Gavrilov DK, Piazza AL, Pino G, et al. The combined impact of CLIR post-analytical tools and second tier testing on the performance of newborn screening for disorders of propionate, methionine, and cobalamin metabolism. Int J Neonatal Screen. 2020;6[2]:33)
Reject Due To
Blood spot specimen that shows serum rings or has multiple layers | Reject |
Insufficient specimen | Reject |
Unapproved filter papers | Reject |
Method Name
Flow Injection Analysis Tandem Mass Spectrometry (FIA-MS/MS)
Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.